Middle East respiratory syndrome: Pathogenesis and therapeutic developments

  • Hani Choudhry
  • , Muhammed A. Bakhrebah
  • , Wesam H. Abdulaal
  • , Mazin A. Zamzami
  • , Othman A. Baothman
  • , Mohammed A. Hassan
  • , Mustafa Zeyadi
  • , Nawal Helmi
  • , Faisal Alzahrani
  • , Ashraf Ali
  • , Mohammad Khalid Zakaria
  • , Mohammad Azhar Kamal
  • , Mohiuddin Khan Warsi
  • , Firoz Ahmed
  • , Mahmood Rasool
  • , Mohammad Sarwar Jamal

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations

Abstract

The first case of Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in the year 2012, which spread rapidly and increased to more than 2200 in 2018. This highly pathogenic virus with high mortality rate is among one of the major public health concerns. Saudi Arabia remains to be the most affected region with the majority of MERS-CoV cases, and currently, no effective drugs and vaccines are available for prevention and treatment. A large amount of information is now available regarding the virus, its structure, route of transmission and its pathophysiology. Therefore, this review summarizes the current understanding of MERS-CoV's pathogenesis, treatment options and recent scientific advancements in vaccine and other therapeutic developments, and the major steps taken for MERS prevention control.

Original languageEnglish
Pages (from-to)237-246
Number of pages10
JournalFuture Virology
Volume14
Issue number4
DOIs
StatePublished - Apr 2019
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Arabian Peninsula
  • MERS
  • SARS
  • Saudi Arabia
  • WHO
  • coronavirus
  • global
  • macrophages
  • therapeutic
  • vaccine

Fingerprint

Dive into the research topics of 'Middle East respiratory syndrome: Pathogenesis and therapeutic developments'. Together they form a unique fingerprint.

Cite this